In Vitro Ravuconazole Susceptibility of Anthropophilic Dermatophyte Strains Isolated from Japanese Patients

DOI Web Site Web Site PubMed 被引用文献1件 参考文献10件
  • Kano Rui
    Department of Veterinary Dermatology, Nihon University College of Bioresource Sciences
  • Hiruma Junichiro
    Department of Dermatology, Tokyo Medical University
  • Yokota Maki
    Department of Veterinary Dermatology, Nihon University College of Bioresource Sciences
  • Noguchi Hiromitsu
    Noguchi Dermatology Clinic Ochanomizu Institute for Medical Mycology and Allergology
  • Hase Midori
    Ochanomizu Institute for Medical Mycology and Allergology
  • Kamata Hiroshi
    Department of Veterinary Dermatology, Nihon University College of Bioresource Sciences
  • Harada Kazutoshi
    Department of Dermatology, Tokyo Medical University
  • Hiruma Masataro
    Ochanomizu Institute for Medical Mycology and Allergology

この論文をさがす

抄録

<p>Ravuconazole (RVCZ) is a new human anti-fungal azole drug available in Japan since 2018 and is a broad-spectrum agent that exhibits excellent activity against dermatophytes. In the present study, the in vitro RVCZ susceptibility of clinical isolates of anthropophilic dermatophytes, including Trichophyton interdigitale strains with either low susceptibility to itraconazole (ITCZ) or resistance to terbinafine (TEBR), was investigated using the Clinical & Laboratory Standards Institute M38-A2 test. The MICs of RCVZ for 20 clinical isolates of T. interdigitale were < 0.03125–0.125 mg/L; for 4 clinical isolates of T. rubrum, < 0.03125–0.0625 mg/L; and for 20 clinical isolates of T. tonsurans, < 0.03125 mg/L. Similarly, the MICs of RCVZ for the T. interdigitale strains with either low susceptibility to ITCZ or resistance to TEBR were also < 0.03125 mg/L. To our knowledge, this is first study to investigate the in vitro RVCZ susceptibility of T. interdigitale strains with either low susceptibility to ITCZ or resistance to TEBR. Our results indicated that RVCZ was the most effective drug against these strains.</p>

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (10)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ